Abstract:Background In China, breast cancer is the most frequently diagnosed cancer in women. Marked disparities between urban and rural populations have been reported for breast cancer incidence and survival. In 2009, China launched a breast cancer screening programme for women living in rural areas who were aged 35–64 years and at average risk. The programme used ultrasound combined with clinical breast examination as the primary screening tool. In 2012, breast cancer screening was done by use of ultrasound, and was followed by mammography among women living in urban areas aged 40–69 years, who were high risk and were identified through risk assessment questionnaires. To date, economic evidence is still scarce. This study aimed to analyse the cost-effectiveness of breast cancer screening compared with no screening among women in rural and urban China. Methods We developed a Markov model to estimate the lifetime costs and effects, from a societal perspective, for the general population-based cohorts, both in urban China with high incidence of breast cancer and rural China with low incidence of breast cancer. Analyses were done for women in rural areas aged 35 years and women in urban areas aged 40 years. Women who were asymptomatic in the intervention arm were screened every 3 years. Breast cancer in the non-screening arm could only be diagnosed on presentation of symptoms. The main outcome measure was cost per quality-adjusted life-year (QALY) gained with a 3% annual discount. Parameter uncertainty was explored using one-way and probabilistic sensitivity analyses. Findings Compared with no screening, the rural breast cancer screening programme cost US$186·72 more and led to a loss of 0·20 QALYs because of disutility from false positives. Breast cancer screening among women in rural China is more expensive, with an incremental cost-effectiveness ratio (ICER) of $-916 per QALY, compared with no screening. In urban areas, the breast cancer screening programme cost $84·99 and gained 0·01 QALYs, with an ICER of $6671 per QALY, well below the willingness-to-pay threshold of $23 050 per QALY at three times GDP per capita (2014) in China. The results are shown to be robust through the sensitivity analyses. Interpretation In a rural setting, which has low breast cancer incidence, screening for asymptomatic disease among the general population using current screening tools is not cost-effective. Priority should be given to ensure that women who are symptomatic have access to diagnosis and treatment at an early stage. In urban China, a high-risk population-based screening method for breast cancer is very likely to be cost-effective compared with no screening. Funding National Natural Science Foundation of China (71273016 and 71673004).

PUK9 Economic Evaluation of Prostate-Specific Antigen Screening for Prostate Cancer in China

Prostate Cancer Screening Using Prostate-Specific Antigen Tests in a High-Risk Population in China: A Cost-Utility Analysis

PP64 Economic Evaluation for Esophageal Cancer Screening in China

Cost-Effectiveness of Lung Cancer Screening using Low-dose Computed Tomography in China: Policy Guidance Based on Start Age and Interval (Preprint)

The Impact of Prostate-Specific Antigen Screening on Prostate Cancer Incidence and Mortality in China: 13-Year Prospective Population-Based Cohort Study

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 Ng/ml.

A cost-benefit analysis of mass prostate cancer screening

Modeling the Cost-effectiveness of Esophageal Cancer Screening in China

Percent Free Prostate-Specific Antigen for Prostate Cancer Diagnosis in Chinese Men with a PSA of 4.0–10.0 Ng/ml: Results from the Chinese Prostate Cancer Consortium

[The Prostate Cancer Precision Screening Program: a Preliminary Report after Recruitment of 2 159 Men].

Risk Assessment Models to Evaluate the Necessity of Prostate Biopsies in North Chinese Patients with 4-50 Ng/ml PSA

The prostate cancer precision screening program:a preliminary report after recruitment of 2159 men

Cost–effectiveness of Risk-Based Breast Cancer Screening Programme, China

Development and External Multicenter Validation of Chinese Prostate Cancer Consortium Prostate Cancer Risk Calculator for Initial Prostate Biopsy.

Early Diagnosis of Prostate Cancer from the Perspective of Chinese Physicians.

Breast Cancer Screening Programme in China: Does One Size Fit All? A Cost-Effectiveness Analysis Based on a Markov Model

MP13-07 COMBINATION OF SERUM PSA, MPMRI AND PROSTATE TARGETED BIOPSY FOR PROSTATE CANCER SCREENING IN NANJING

Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong

Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis

Epidemiological and Economic Evaluation of Breast Cancer Screening in Urban Population in China: a Multitarget Calibrated Modelling Study

Polygenic risk-stratified screening for nasopharyngeal carcinoma in high-risk endemic areas of China: a cost-effectiveness study